Home

Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer

TW's Take: this is a coming out party of sorts for Aevitas, another partner company in Fortress' stable. The "alternative complement pathway" space is...

Trading Blog, Feb. 25th 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of...

TW's Take: $20M into the coffers of Fortress Bio (FBIO) along with a PRV worth around $100M by the summer of 2023 is great...

Miami Advice

The past year has been all about the pandemic. First it was about selling everything. Like every other market meltdown, it was viewed as...

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States...

TW's Take: These are very important data as TFF continues to prove the viability of the thin film freezing technology in vaccine development. The...

Trading Blog, Feb. 18th, 2021

I thought I'd put out a lengthier note today as I have gotten a lot of new subscribers over the last month and they...

Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates

TW's Take: with various strains of Covid-19 appearing, one could see the disease being here for many years and a therapeutic being greatly needed....

Heard On The Street

When I started in this business in the 1980s, "Heard on the Street" was a market moving column in the Wall Street Journal. R....

LexaGene Announces Change in Management and Appoints New Member to the Board of Directors

TW's Take: this is really a non-event for LexaGene, in terms of the business, however it is nice to get someone with a very...

HJLI Tried To Ruin 2019 For Me…2021 Should Be A Different Story

Yes, I'm back in Hancock Jaffe (HJLI). After taking major losses last year in the stock, I've decided to jump back in the pool....

Atomera Provides Fourth Quarter and Fiscal 2020 Results

TW's Take: nothing exciting in this report...just that the company continues to execute on their business plan. The rest of the year should see...

LEXAGENE’S MIQLAB SUCCESSFULLY DETECTS MUTANT UK AND SOUTH AFRICAN COVID-19 SEQUENCES

TW's Take: while they will not incorporate these tests into their EUA application, LexaGene will be able to roll out additional tests broadly post...

Sequans Communications Announces Fourth Quarter 2020 and Full Year 2020 Financial Results

TW's Take: SQNS is setting up for a very big 2021. Guidance of 50% annual revenue growth over the next 4 years makes this...

Riding the Waves

This is without a doubt the most amazing market of my career. It's obviously a bull market as indexes continue to head higher. But,...

Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked...

TW's Take: nice to have the clinical hold removed, allowing this program to proceed. MBIO is a compelling valuation (thanks to PRVs) in biotech,...

The GameStop Impact…January In Review

What a crazy way to end a wild month, huh? As GameStop (GME) continued to rally in the face of shorts, Robin Hood required...

Sequans Receives Major Funding Award for 5G Development From French Government

TW's Take: a solid endorsement of SQNS' technology, this grant leaves them likely fully-funded as they are guiding towards breakeven sometime around year end...

ParkerVision Gets Inside Track On Intel In Markman Ruling

A Markman Hearing is a pretrial hearing in a U.S. District Court during which a judge examines evidence to determine the appropriate meanings of relevant key...

Trading Blog, Jan. 26, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

Texas Court’s Markman Ruling Favorable for ParkerVision

TW's Take: this is great news for PRKR. Not only does it set them up very well in this large patent case versus Intel,...

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $250 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.